SCHEMBL29806705

SCHEMBL29806705

COc1cnc(N(C(=O)OC(C)(C)C)c2ccc(C(F)(F)F)cc2)c(C(=N)NO)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 4/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ HDAC3 O15379 3/20 0.33
▸ HDAC1 Q13547 3/20 0.33
▸ HDAC2 Q92769 3/20 0.33
▸ HDAC6 Q9UBN7 3/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CPB2 Q96IY4 1/20 0.33
▸ SORT1 Q99523 1/20 0.32
▸ MT-CO2 P00403 1/20 0.31
▸ MMP2 P08253 1/20 0.31
▸ MMP9 P14780 1/20 0.31
▸ DYRK3 O43781 1/20 0.31
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ DYRK2 Q92630 1/20 0.31
▸ DYRK1B Q9Y463 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24755009 1.00 LIPE (0.35) LIPEABCG2HDAC3HDAC1HDAC2
SCHEMBL24755070 0.82 NQO2 (0.35) MAPTLMNA
SCHEMBL24755151 0.82 HDAC3 (0.33) LIPEHDAC3HDAC1HDAC2HDAC6
SCHEMBL22931772 0.80 LIPE (0.37) LIPEABCG2NPC1MAPTCPB2
SCHEMBL29806156 0.80 LIPE (0.37) LIPEABCG2NPC1MAPTCPB2
SCHEMBL22931782 0.78 RXRA (0.33) HDAC3HDAC1HDAC2HDAC6MAPT
SCHEMBL29806167 0.78 RXRA (0.33) HDAC3HDAC1HDAC2HDAC6MAPT
SCHEMBL22931775 0.74 RXRA (0.32) LIPEHDAC3HDAC1HDAC2HDAC6
SCHEMBL29420832 0.74 RXRA (0.32) LIPEHDAC3HDAC1HDAC2HDAC6
SCHEMBL22931773 0.73 LIPE (0.33) LIPEABCG2HDAC1HDAC6MT-CO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003983-A1 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER Basilea Pharmaceutica International AG (CH) 2022-06-01 — — EP disclosed
Send feedback